Egypt launches locally produced Insulin Glargivin

Egypt launched its first batch of locally produced Insulin Glargivin on Wednesday at Eva Pharma, marking a significant milestone for the country’s pharmaceutical industry. This initiative follows a partnership with Eli Lilly aimed at localising insulin production, with the objective of meeting both local and international demand.

This achievement strengthens Egypt’s pharmaceutical sector and supports President Abdel Fattah El-Sisi’s vision for local manufacturing and self-sufficiency. It also enhances Egypt’s biotechnology and pharmaceutical manufacturing capabilities, promoting scientific research and innovation. The Egyptian Drug Authority (EDA) is dedicated to ensuring that Egyptian-made products meet global standards of quality and reliability.

Insulin is one of the world’s best-selling drugs, experiencing a compound annual growth rate of 19 per cent from 2019 to 2023. Local production is expected to significantly reduce Egypt’s import bill, which reached $30 million for insulin alone by the end of September. With Eva Pharma’s production capacity of up to 100 million insulin vials annually, this project will not only secure a stable local supply but also position Egypt as a key exporter. Under the partnership, insulin will be exported to 56 countries.

Attribution: Egyptian Drug Authority (EDA)

Subediting: Y.Yasser